Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

09. Februar 2017 08:00 ET | Quelle: PetLife Pharmaceuticals, Inc.

World Renowned Veterinary Nutritionist Dr. R. Geoffrey Broderick Continues Groundbreaking Efforts to Help Animals by Joining PetLife Pharmaceuticals, Inc. as the Chairman of Product Development and Advisory Board

Hancock, MD, Feb. 09, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications...
10. Januar 2017 08:00 ET | Quelle: PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals reports the First of Three Preclinical Studies in their pre-INAD Process for Vitalzul. Blue Scorpion Venom Toxicity Study Results Show No Adverse Reactions across Multiple Dosing Levels.

Hancock, MD, Jan. 10, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
07. Dezember 2016 08:50 ET | Quelle: PetLife Pharmaceuticals, Inc.

Correction: PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line

Hancock, MD, Dec. 07, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
15. November 2016 08:00 ET | Quelle: PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals Notes Recent Cuban Research Providing Profound Evidence of Caribbean Blue Scorpion Venom's Ability to Eradicate Cancer Cells as Continued Support for PetLife's pre- INAD Studies of Vitalzul™

Hancock, MD, Nov. 15, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
24. Oktober 2016 12:00 ET | Quelle: PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals Announces the Addition of a Seasoned Marketing Specialist and Investor, Mrs. Vyvyan Campbell, to the Board of Directors

Hancock, MD, Oct. 24, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
19. Oktober 2016 15:15 ET | Quelle: PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals Announces the Addition of Dr. Simon Wood PhD as the Company’s new Scientific Officer with plans to expand its Current Portfolio of Veterinarian Drugs and Nutraceuticals

Hancock, MD, Oct. 19, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
17. Oktober 2016 08:00 ET | Quelle: PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals is Pleased to Announce the Completion of the New Company Website

Hancock, MD, Oct. 17, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
13. Oktober 2016 08:00 ET | Quelle: PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals Expands Cell Line Study with InnoVision in Preparation for FDA/CVM Registration Submission

Hancock, MD, Oct. 13, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
10. Oktober 2016 08:00 ET | Quelle: PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals is Pleased to Showcase its New “Vitalzul™ Information Video” along with a Corporate Update

Hancock, MD, Oct. 10, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
28. September 2016 10:30 ET | Quelle: PetLife Pharmaceuticals, Inc.

PetLife Pharmaceuticals Explores Product Expansion with Strategic Partner(s); Successfully Presents at Two Financial Conferences in September

Hancock, MD , Sept. 28, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLFD) (the "Company"), the developer of Vitalzul™, a new generation of high potency veterinary cancer...

Nächste Seite